Media
November, 2019, an article in MIRROR REVIEW, 4HF BIOTEC: A Novel Approach For Cancer Treatment.
-----------------------------------
October 26 - 30, 2019, 4HF Biotec will be presenting at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston
Posters :
# C075 - “The use of 4HF Cancer Data Miner platform for an In Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib”
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date: Tuesday, October 29 -12.30 -16 PM
# C060 – “Broad spectrum activity of the MDM2 inhibitor MI-773 in hematologic and solid cancer cell lines in-vitro and determination of predictive biomarkers”
Session Title: Therapeutic Agents-- Other
Session Date: Tuesday, October 29 -12.30 -16 PM
-----------------------------------
October 8 -11, 2019, 4HF Biotec will be presenting in collaboration with Bionavigen at 10th Annual World ADC, San Diego
Poster entitled :
#01 - "4HF Cancer Data Miner platform for an accelerated
In Silico ADC target discovery and evaluation"
-----------------------------------
July 2019, StartupCity selected 4HF Biotec in the top 15 most promising Biotec startups in Europe
Links:
https://biotech-europe.startupcity.com/vendors/top-biotech-startups-in-europe-2019.html
-----------------------------------
18th July 2019, 4HF Biotec today announces that it has entered into a collaboration with Bionavigen in the field of target and drug discovery.
-----------------------------------
Mar 2019, 4HF will participate at the AACR ANNUAL MEETING 2019, Mar 29-Apr 3, Atlanta, United States.
Visit our posters: Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers. Abstract nr 2196.
and,
Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers. Abstract nr 3074.
------------------------------------
Nov 2018, 4HF Biotec will participate at the 30th EORTC-NCI-AACR SYMPOSIUM : Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that will take place 13-16 Nov, Dublin, Ireland. We will be very pleased to meet you there!
Visit our poster: #PB-039, Title : Broad spectrum activity of Sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers. Section "Molecular Targeted Agents" on 13 November 2018
------------------------------------
Apr 2018, 4HF Biotec will participate at the AACR Annual Meeting 2018 April 14-18, Chicago, Illinois, USA
-----------------------------------
Mar 2018, 4HF Biotec will participate at the World ADC 2018, 26–28 March, Berlin, Germany
------------------------------------
Feb 2018, 4HF Biotec will participate at the 39th EORTC-PAMM Winter Meeting; 7-10Feb, Roma, Italy
-----------------------------------
Oct 2017, 4HF Biotec will participate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that will take place October 26-30, 2017, Philadelphia, Pennsylvania.
We will take this opportunity to present our poster #B167, entitled : ”KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 Inhibitor” October 29, 2017, 12:30 - 4:00 PM, Hall E
We are very pleased to meet you at this event, do not hesitate to visit our poster or to contact us for a discussion.
